You are here

Global Thrombosis Drugs Market Forecast up to 2024: High Preference of Anticoagulant Drug Usage is Expected to Boost the Segment

DUBLIN, March 11, 2019 /PRNewswire/ -- The "Thrombosis Drugs Market Forecast up to 2024" report has been added to ResearchAndMarkets.com's offering.

The global thrombosis drugs market is estimated to witness a CAGR of 9.5% during the forecast period 2018-2024

The thrombosis drugs market by drug class is segmented into factor Xa inhibitor, low molecular weight heparin, and P2Y12 platelet inhibitor. The factor Xa inhibitor segment occupied a significant market share in 2017 and is expected to grow at a high CAGR during the forecast period. The high preference of anticoagulant drug usage is expected to boost the segment growth during the forecast period.

Indication Analysis:

The thrombosis drugs market by indication is segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. The pulmonary embolism segment occupied a significant share in 2017 and is anticipated to grow at a high CAGR during the forecast period. Increasing focus on the development of low-cost drugs and large patient pool with pulmonary embolism condition are likely to propel the market growth in the next five years.

Region Analysis:

North America is the major shareholder in the global thrombosis drugs market, followed by Europe. The availability of novel anticoagulants, the presence of dominant market players, increased disease awareness, and rising healthcare expenditure make North America a dominant shareholder in the market. Asia Pacific is the fastest growing region due to an upsurge in the prevalence of cardiovascular disease & other age-related chronic diseases, growing healthcare expenditure, and increasing access to healthcare services.

Competitive Analysis:

Due to the increasing demand for thrombosis drugs in recent years, many companies are collaborating to develop novel drugs, and new thrombosis drugs have been launched and approved globally. For instance, in December 2017, Aurobindo Pharma received FDA approval to manufacture and market its generic version of Fondaparinux Sodium injection used to prevent DVT.

Janssen Pharmaceuticals, in late 2017, announced the launch of XARELTO (rivaroxaban) for reducing the sustained risk of recurrent venous thromboembolism (VTE). In June 2017, Portola launched its drug betrixaban (Bevyxxa) in the US market. In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor and backup compounds.

Key Topics Covered:

1 Industry overview
1.1.1 Global Driver for Pharmaceutical Demand
1.1.2 Pharmaceutical spending region wise
1.1.3 R&D pipeline in pharmaceutical industry
1.1.4 Top pharma drugs by sales in 2017 ($Million)
1.2 Industry Trends

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition
3.2 Causes of thrombosis
3.3 Risk factors for thrombosis
3.4 Symptoms of thrombosis
3.5 Diagnosis of thrombosis
3.6 Segmented Addressable Market (SAM)
3.7 Trends of the thrombosis drugs market
3.8 Related Markets
3.8.1 Over-the-Counter (OTC) drugs
3.8.2 Cardiovascular drugs
3.8.3 Respiratory drugs

4 Market Outlook
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5 Forces

5 Market Characteristics
5.1 DRO - Global Thrombosis Drugs Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing burden of cardiovascular disease and trauma cases across the globe
5.1.1.2 Upsurge in the geriatric and obese population
5.1.2 Opportunities
5.1.2.1 Increase in health care spending and demand for better treatment in emerging economies
5.1.2.2 Increasing new product launch and R&D activities
5.1.3 Restraints
5.1.3.1 Side effects associated with thrombosis drugs
5.1.3.2 Lack of awareness among about thromboembolism conditions
5.2 DRO - Impact Analysis
5.3 Key Stakeholders

6 Drug Class: Market Size and Analysis
6.1 Overview
6.2 Factor Xa Inhibitors
6.3 Low Molecular Weight Heparin
6.4 P2Y12 platelet inhibitors

7 Indications: Market Size and Analysis
7.1 Overview
7.2 Deep vein thrombosis (DVT)
7.3 Pulmonary embolism
7.4 Atrial fibrillation

8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 Rest of the World

9 Competitive Landscape
9.1 Overview

10 Vendor Profiles
10.1 Aspen Pharmacare Holdings Limited
10.1.1 Overview
10.1.2 Business Unit
10.1.3 Geographic Presence
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategy
10.2 Johnson & Johnson
10.3 Sanofi S.A.
10.4 Boehringer Ingelheim GmbH
10.5 Bayer AG
10.6 Bristol-Myers Squibb

11 Companies to Watch For
11.1 AstraZeneca plc
11.1.1 Overview
11.1.2 AstraZeneca plc: Recent Developments
11.2 Pfizer, Inc.
11.3 Baxter International Inc
11.4 Daiichi Sankyo

For more information about this report visit https://www.researchandmarkets.com/research/57qxjc/global_thrombosis?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-thrombosis-drugs-market-forecast-up-to-2024-high-preference-of-anticoagulant-drug-usage-is-expected-to-boost-the-segment-300809341.html

SOURCE Research and Markets